Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.

Novo Nordisk saw its stock drop 21% year-to-date, pressured by weaker-than-expected obesity drug trial results.

LONDON/COPENHAGEN (Reuters) -Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk (NYSE: NVO ), ...

Learn more about whether Jazz Pharmaceuticals plc or Novo Nordisk A/S is a better investment based on AAII's A+ Investor ...

Investing.com -- Barclays has lowered its first-quarter 2025 estimates for Novo Nordisk (CSE: NOVOb) (NYSE: NVO) ahead of its ...

Bagsværd, Denmark Tuesday, April 1, 2025, 18:00 Hrs [IST] ...

In the realm of investing, finding value in mega-cap stocks can often seem like searching for a needle in a haystack. Nvidia ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several ...

Learn more about whether Corcept Therapeutics Incorporated or Novo Nordisk A/S is a better investment based on AAII's A+ ...

Novo Nordisk Pharmaceutical Industries, a leading global healthcare company, has donated STEM kits to the Boys and Girls Club ...